InMed Pharmaceuticals (INM) Current Leases (2020 - 2026)

InMed Pharmaceuticals has reported Current Leases for 7 years, with the latest figure at $389381.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 9.29% year-over-year to $389381.0; the trailing twelve-month figure through Mar 2026 stood at $389381.0 (down 9.29% YoY), and the FY2025 full-year result was $435507.0, up 37.04% from the prior year.
• Current Leases for Q1 2026 stood at $389381.0, down from $408122.0 in the prior quarter.
• The five-year high for Current Leases was $435507.0 in Q2 2025, with the low at $292998.0 in Q3 2023.
• Historically, Current Leases has averaged $392556.5 across 5 years, with a median of $404276.0 in 2022.
• Annual changes were most pronounced in 2022 — Current Leases soared 407.38% — and 2023, when it fell 27.5%.
• InMed Pharmaceuticals' Current Leases stood at $414307.0 in 2022, then decreased by 12.1% to $364190.0 in 2023, then gained by 15.25% to $419711.0 in 2024, then dropped by 2.76% to $408122.0 in 2025, then dropped by 4.59% to $389381.0 in 2026.
• The last three Current Leases figures came in at $389381.0 (Q1 2026), $408122.0 (Q4 2025), and $424765.0 (Q3 2025), per Business Quant data.